- Kenvue shares edged up about 0.33% at the close and added roughly 0.11% after hours following news of its upcoming earnings release schedule tied to the pending Kimberly-Clark deal.
- Analysts remain largely cautious, with average price targets near $18.90 and several firms trimming targets or reiterating Hold/Equal Weight ratings amid retail softness and legal overhangs.
- The stock’s modest gains came as broader U.S. markets stayed volatile, with traders now focused on earnings results and regulatory progress on the acquisition as the next major catalysts.
Shares of Kenvue Inc. (NYSE: KVUE) finished modestly higher in the most recent trading session, responding to fresh corporate news that the company has set a Feb. 17, 2026 date to release its fourth-quarter and full-year 2025 results and will forego a traditional earnings call, a move that has drawn investor attention amid its pending acquisition by Kimberly-Clark. Regular session trading saw KVUE close at $18.13, up approximately +0.33% from the prior session’s close, before drifting slightly in after-hours dealings to hover near $18.15, a further uptick of around +0.11% in extended trading.(Investing)
The latest session’s gains come against a backdrop of heightened scrutiny on Kenvue’s valuation, deal arbitrage and fundamental outlook. Kenvue’s press release confirms the earnings announcement timing as part of its calendar — with no accompanying earnings call — reflecting both the company’s near-term visibility priorities and the impact of its pending Kimberly-Clark takeover. Traders initially responded with caution to the absence of guided commentary that typically accompanies quarterly calls, choosing instead to parse earnings timing and expected deliverables.(Kenvue)
On the brokerage front, Wall Street consensus continues to skew Neutral to Buy, underpinned by an average analyst price target near $18.92 over the next 12 months, suggesting modest upside from current levels. Investing.com’s consensus data shows most analysts rating KVUE shares as Hold, with the average target slightly above market prices — though the range diverges, with high estimates nearing $23 and lower targets in the $17–$18 zone.(stockanalysis)
Opinions remain mixed. A Jefferies note trimmed its price target to roughly $18 from a previous higher level recently, reflecting concerns about slower retail trends, while Barclays has maintained an “Equal Weight” stance with an $18 target, translating into subdued near-term enthusiasm among some Wall Street strategists. Broader thematic risks — including ongoing litigation exposures tied to legacy product lines and macro consumer trends — have kept investor sentiment cautious where valuation multiples are concerned, as reflected in the dispersion of targets.(Investing)
Contrast this with broader market movement on the same trading day: major U.S. benchmarks experienced uneven action. The S&P 500 has been navigating near key technical thresholds after recent weakness in breadth and rising volatility, underscoring a risk-off tone in equity markets that has overlapped with sector rotations out of consumer staples and healthcare-adjacent names. In that context, Kenvue’s modest advance outperformed some peers, albeit within a narrow intraday range.(marketwatch)